Tanakan tablets p/o 40mg №15×6

Name:
Tanakan tablets 40mg in blister pack No. 15×6
Description:
Oral solution – brownish-orange color with a characteristic odor. Film-coated tablets – biconvex, round, brick-red coated. On a break, the tablets have a light brown color and a specific odor. Main active ingredient Ginkgo biloba leaf extract Release form 15 tablets in a PVC/Aluminum foil blister. 2 or 6 blisters, together with the leaflet, are placed in a cardboard box. Dosage 40 mg ml Special instructions Before starting the drug, consult your doctor. With caution, the drug should be prescribed simultaneously with other drugs, the metabolism of which is realized through cytochrome P450-3A4 (CYP3A4). Since the drug contains lactose, it should not be prescribed to patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or lactase deficiency. The use of the drug is contraindicated in children and adolescents under 18 years of age due to the lack of sufficient data. Patients with an increased risk of bleeding (hemorrhagic diathesis), as well as patients taking anticoagulant and antiplatelet agents, should consult a doctor before taking the drug. Medicines containing ginkgo biloba may increase the risk of bleeding. The drug should be stopped 3-4 days before surgery. In patients with epilepsy, taking ginkgo biloba preparations can provoke the development of a seizure. The simultaneous use of ginkgo biloba and efavirenz is not recommended (see section “Interaction with other drugs”). If symptoms persist or worsen while taking the medicine, consult a doctor. Interaction with other drugs and other forms of interaction The results of clinical trials of drug interactions of EGb761 with other drugs have demonstrated either an increase or inhibition of the activity of cytochrome P450 isoenzymes. So the levels of midazolam changed after the introduction of EGb 761, presumably due to their mutual effect on CYP3A4. Ginkgo biloba preparations should be used with caution with drugs metabolized through CYP3A4, as well as with drugs that have a narrow therapeutic index. Drugs based on ginkgo biloba, when taken simultaneously with anticoagulant agents (for example, phenprocoumon, warfarin) or antiplatelet agents (for example, clopidogrel, acetylsalicylic acid and other non-steroidal anti-inflammatory drugs), can cause a change in their action. The conducted studies did not reveal the interaction of ginkgo biloba preparations with warfarin, however, when they are taken together, it is recommended to carry out adequate monitoring of blood coagulation parameters at the beginning of the intake, when changing the dose, ending the intake, or when replacing the ginkgo biloba preparation. Interaction studies with talinolol have shown that ginkgo biloba preparations can inhibit P-glycoprotein in the gut. This may lead to increased exposure to drugs whose metabolism is dependent on P-glycoprotein, such as dabigatran etexilate. Caution should be exercised when ginkgo biloba and dabigatran are coadministered. Ginkgo biloba can increase the Cmax of nifedepine (in some individuals up to 100%), which is accompanied by dizziness and increased hot flashes. Co-administration of ginkgo biloba and efavirenz is not recommended as plasma concentrations of efavirenz may be reduced due to CYP3A4 induction. In the case of simultaneous use of other medicines, including those sold without a doctor’s prescription, you should consult a doctor. Pharmacological action Tanakan has a neuroprotective effect and prevents the formation of free radicals. Pharmacodynamics Improves the supply of oxygen and glucose to the brain, normalizes the tone of arteries and veins, improves microcirculation, improves blood flow, prevents erythrocyte aggregation; has an inhibitory effect on platelet activating factor; improves metabolic processes, has an antihypoxic effect on tissues; prevents the formation of free radicals and lipid peroxidation of cell membranes; affects the release, reuptake and catabolism of neurotransmitters (norepinephrine, acetylcholine) and their ability to bind to membrane receptors. Indications for use Encephalopathy of various origins with disorders of attention, memory, decreased intellectual abilities, sleep disturbance; violations of peripheral circulation and microcirculation; neurosensory disorders of vascular origin – visual impairment, hearing impairment, coordination disorders; asthenic conditions. Dosage and administrationTanakan is prescribed 120 mg per day (1 tablet or 1 ml of solution 3 times a day), orally, during meals. In the treatment of asthenic disorders, the daily dose is 240 mg (2 tablets or 2 ml of solution 3 times a day). The duration of the course of treatment with Tanakan is from 1 to 3 months. The tablets should be taken with half a glass of water, the oral solution should be dissolved in half a glass of water. When taking the drug in the form of a solution, use the supplied dosing pipette. Application during pregnancy and lactation Instructions for use Tanakan 30 pcs. tablets Composition and form of release Oral solution – 100 ml: dry standardized ginkgo biloba extract (EGb 761) – 4000.00 mg (content of ginkgo heterosides – 24%; ginkgolides-bilobalides – 6%) excipients: sodium saccharinate; orange essence soluble; lemon essence soluble; ethanol (95%), purified water – up to 100 ml In dark glass bottles of 30 ml (complete with dosing pipette); in a pack of cardboard 1 bottle. Film-coated tablets – 1 tab.: ginkgo biloba dry standardized extract (EGb 761) – 40.00 mg (content of ginkgo heterosides – 24%; ginkgolides-bilobalides – 6%) excipients: core: lactose monohydrate; MCC; corn starch; silicon dioxide colloidal; talc; magnesium stearate shell: hypromellose; macrogol 400; macrogol 6000; titanium dioxide; iron oxide red In blister packs 15 pcs.; in a carton pack of 2 or 6 packs.